Clinical Trial Update: A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of MK-0431D (fixed-dose sitagliptin/simvastatin) for type 2 diabetes patients on metformin was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0431D (sitagliptin and simvastatin fixed-dose combination)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2014-10-22